Albendazole 500 mg

Cipla Ltd offers wide range of formulation products which includes albendazole 2500 mg. Dosage form: bolus. Contact us for more information.

Cipla Ltd offers wide range of veterinary products which includes albendazole 30% w/w. Dosage form: powder. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes albendazole 300 mg. Dosage form: bolus. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes albendazole 3000 mg. Dosage form: bolus. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes albendazole 40 mg/ml. Dosage form: oral suspension. Therapeutic area: antiinfectives. Packaging type: bottle. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes albendazole 400 mg. Dosage form: tablets. Therapeutic area: antiinfectives. Packaging type: strip. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes albendazole 600 mg. Dosage form: bolus. Contact us for more information.

Cipla Ltd offers wide range of api which includes albuterol sulphate. It belongs to albuterol sulphate category. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes alendronate sodium 10 mg. Dosage form: tablets. Therapeutic area: musculoskeletal. Packaging type: blister. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes alendronate sodium 35 mg. Dosage form: tablets. Therapeutic area: musculoskeletal. Packaging type: blister. Contact us for more information.

Cipla Ltd offers wide range of formulation products which includes alendronate sodium 70 mg. Dosage form: tablets. Therapeutic area: musculoskeletal. Packaging type: blister. Contact us for more information.

Cipla Ltd offers wide range of api which includes alendronate sodium trihydrate. It belongs to alendronate sodium trihydrate category. Contact us for more information.

The agreement is expected to accelerate Cipla’s global lung leadership agenda